Across TCGA pan-cancer cohorts, SMYD4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMYD4 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMYD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMYD4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, MESO, and UCEC are the cancer types where SMYD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.199	0.752	<.001	72	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SMYD4 tumor-vs-normal RNA expression · all SMYD4 data types